Daxor Corporation Announces Cabrini Medical Center Of Manhattan To Initiate Blood Optimization Program And Acquire Blood Volume Analyzer

NEW YORK--(BUSINESS WIRE)--June 28, 2006--Daxor Corporation (AMEX:DXR - News), a medical instrumentation and biotechnology company, received a signed agreement from Cabrini Medical Center of Manhattan, establishing the nation's first Blood Optimization Program(TM) through Daxor's subsidiary, Idant Laboratories. As part of the program, Cabrini will acquire a BVA-100 Blood Volume Analyzer to perform blood volume studies. The Blood Optimization Program(TM) involves measurement of a patient's blood volume prior to elective surgery, storage of blood in a frozen state, and treatment with blood stimulants such as epoietin alpha to increase blood production. The goal of the program is to avoid having patients enter surgery in a blood depleted state and also to have their own blood available to replace blood lost during surgery.